The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016

被引：168

作者：

Tan, Daniel S. W. ^{[1
,2
]}

Yom, Sue S. ^{[3
]}

Tsao, Ming S. ^{[4
,5
]}

Pass, Harvey I. ^{[6
]}

Kelly, Karen ^{[7
]}

Peled, Nir ^{[8
]}

Yung, Rex C. ^{[9
]}

Wistuba, Ignacio I. ^{[10
]}

Yatabe, Yasushi ^{[11
]}

Unger, Michael ^{[12
,13
]}

Mack, Philip C. ^{[7
]}

Wynes, Murry W. ^{[14
]}

Mitsudomi, Tetsuya ^{[15
]}

Weder, Walter ^{[16
]}

Yankelevitz, David ^{[17
]}

Herbst, Roy S. ^{[18
]}

Gandara, David R. ^{[7
]}

Carbone, David P. ^{[19
]}

Bunn, Paul A., Jr. ^{[20
]}

Mok, Tony S. K. ^{[21
]}

Hirsch, Fred R. ^{[20
]}

机构：

[1] Natl Canc Ctr Singapore, Singapore, Singapore

[2] Genome Inst Singapore, Singapore, Singapore

[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA

[4] Princess Margaret Canc Ctr, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada

[5] Univ Toronto, Toronto, ON, Canada

[6] NYU, Dept Cardiothorac Surg, Langone Med Ctr, New York, NY USA

[7] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA

[8] Tel Aviv Univ, Thorac Canc Unit, Davidoff Canc Ctr, IL-69978 Tel Aviv, Israel

[9] Greater Baltimore Med Ctr, Dept Pulm & Crit Care Med, Baltimore, MD USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA

[11] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan

[12] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA

[13] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[14] Int Assoc Study Lung Canc, Aurora, CO USA

[15] Kinki Univ, Div Thorac Surg, Dept Surg, Fac Med, Osaka, Japan

[16] Univ Zurich Hosp, Div Thorac Surg, Zurich, Switzerland

[17] Mt Sinai Sch Med, Dept Radiol, New York, NY USA

[18] Yale Canc Ctr, New Haven, CT USA

[19] Ohio State Univ, Div Med Oncol, Columbus, OH 43210 USA

[20] Univ Colorado, Ctr Canc, Div Med Oncol, Aurora, CO USA

[21] Chinese Univ Hong Kong, State Key Lab Southern China, Hong Kong Canc Inst, Dept Clin Oncol,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 07期

关键词：

Non-small cell lung cancer; EGFR mutation; Tyrosine kinase inhibitor; Therapy; Resistance; Brain metastases; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; BRAIN RADIATION-THERAPY; DOSE WEEKLY ERLOTINIB; ACQUIRED-RESISTANCE; T790M MUTATION; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-III;

D O I：

10.1016/j.jtho.2016.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer.(NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-the-art review of the contemporary issues in managing this unique subgroup of patients. (C) 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：946 / 963

页数：18

共 128 条

[1]

[Anonymous], MOL CANC THER

[2] Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].

Arcila, Maria E. ;

Oxnard, Geoffrey R. ;

Nafa, Khedoudja ;

Riely, Gregory J. ;

Solomon, Stephen B. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Pao, William ;

Miller, Vincent A. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180

[3] An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer [J].

Ashworth, Allison B. ;

Senan, Suresh ;

Palma, David A. ;

Riquet, Marc ;

Ahn, Yong Chan ;

Ricardi, Umberto ;

Congedo, Maria T. ;

Gomez, Daniel R. ;

Wright, Gavin M. ;

Melloni, Giulio ;

Milano, Michael T. ;

Sole, Claudio V. ;

De Pas, Tommaso M. ;

Carter, Dennis L. ;

Warner, Andrew J. ;

Rodrigues, George B. .

CLINICAL LUNG CANCER, 2014, 15 (05) :346-355

[4] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[5] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[6] Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network [J].

Beau-Faller, M. ;

Prim, N. ;

Ruppert, A. -M. ;

Nanni-Metellus, I. ;

Lacave, R. ;

Lacroix, L. ;

Escande, F. ;

Lizard, S. ;

Pretet, J. -L ;

Rouquette, I. ;

de Cremoux, P. ;

Solassol, J. ;

de Fraipont, F. ;

Bieche, I. ;

Cayre, A. ;

Favre-Guillevin, E. ;

Tomasini, P. ;

Wislez, M. ;

Besse, B. ;

Legrain, M. ;

Voegeli, A. -C. ;

Baudrin, L. ;

Morin, F. ;

Zalcman, G. ;

Quoix, E. ;

Blons, H. ;

Cadranel, J. .

ANNALS OF ONCOLOGY, 2014, 25 (01) :126-131

[7] Surgical management of non-small cell lung cancer with synchronous brain metastases [J].

Bonnette, P ;

Puyo, P ;

Gabriel, C ;

Giudicelli, R ;

Regnard, JF ;

Riquet, M ;

Brichon, PY .

CHEST, 2001, 119 (05) :1469-1475

[8] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[9] EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas [J].

Chen, Zhi-Yong ;

Zhong, Wen-Zhao ;

Zhang, Xu-Chao ;

Su, Jian ;

Yang, Xue-Ning ;

Chen, Zhi-Hong ;

Yang, Jin-Ji ;

Zhou, Qing ;

Yan, Hong-Hong ;

An, She-Juan ;

Chen, Hua-Jun ;

Jiang, Ben-Yuan ;

Mok, Tony S. ;

Wu, Yi-Long .

ONCOLOGIST, 2012, 17 (07) :978-985

[10] Clinical Characteristics and Treatment Outcomes of Lung Adenocarcinomas with Discrepant EGFR Mutation Testing Results Derived from PCR-Direct Sequencing and Real-Time PCR-Based Assays [J].

Chiu, Chao-Hua ;

Ho, Hsiang-Ling ;

Chiang, Chi-Lu ;

Lin, Shiou-Fu ;

Ma, Hsiu-Hsun ;

Chuang, Yu-Ting ;

Lin, Kun-Yang ;

Tsai, Chun-Ming ;

Chou, Teh-Ying .

JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (01) :91-96

← 1 2 3 4 5 6 7 8 9 10 →